Efficacy and safety evaluation of dabigatran etexilate in the treatment of elderly non-valvular atrial fibrillation
10.12206/j.issn.2097-2024.202207029
- VernacularTitle:达比加群酯治疗老年非瓣膜性心房颤动的有效性和安全性评价
- Author:
Ting LI
1
,
2
;
Kourong SHI
2
;
Zhi LI
3
;
Ziyu WANG
4
;
Ailin CAO
5
;
Jiao QIAN
5
Author Information
1. Department of Pharmacy, the First Affiliated Hospital of Naval Medical University, Shanghai 200433, China
2. Department of Pharmacy, the Seventh People's Hospital of Shanghai University of TCM, Shanghai 200137, China.
3. Department of Pharmacy, the First Hospital of Lianyungang, Lianyungang 222000, China.
4. Department of Pharmacy, Huadong Hospital, Fudan University, Shanghai 200040, China.
5. Department of Pharmacy, the First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
- Keywords:
dabigatran etexilate;
nonvalvular atrial fibrillation;
efficacy;
safety
- From:
Journal of Pharmaceutical Practice
2023;41(9):557-560
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of dabigatran etexilate in the treatment of elderly patients with non-valvular atrial fibrillation (NVAF), so as to provide reference for clinical treatment and rational drug use. Methods Eighty elderly patients with NVAF in The Seventh People's Hospital of Shanghai from December 2020 to June 2021, aged 65 to 80 years, were enrolled in a self-controlled study. Dabigatran etexilate 110 mg was given orally, twice a day (one in the morning and one in the evening) for 6 months. During the follow-up visit, the coagulation function indexes including APTT, TT, FIB and D-D were observed in patients taking medicine for 1 month and 6 months. Liver function indexes including ALT, AST and TBIL, renal function indicators including UREA and eGFR, and blood routine indexes including HGB and ESR, also were observed in patients taking medicine for 1 month and 6 months. Results Patients were compared at 1 month and 6 months after treatment with dabigatran and before: the difference of coagulation function indexes as APTT and TT was statistically significant (P<0.05);There was no significant difference in liver function index, renal function index and blood routine index (P>0.05); A total of 25 adverse events occurred, and the incidence rate of adverse reactions was 31.25%, there was no adverse events such as serious hemorrhage，life threatening and organ failure hemorrhage occurred．Conclusion Dabigatran has good efficacy and safety in the treatment of the elderly NVAF.
